Clinical Trials
12 trialsNCT02496663 2026-05-13
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04285671 2026-03-10
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT00981058 2025-06-18
SQUIRE
Eli Lilly and Company
Phase 3 Completed
NCT03944772 2025-01-30
ORCHARD
AstraZeneca
Phase 2 Active not recruiting
NCT02789345 2024-02-05
A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03054038 2022-04-14
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT00982111 2022-01-11
INSPIRE
Eli Lilly and Company
Phase 3 Completed
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT02451930 2020-10-05
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
Eli Lilly and Company
Phase 1 Completed
NCT02411591 2020-07-09
A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT01606748 2019-09-30
A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin
Eli Lilly and Company
Phase 2 Completed
NCT01788566 2016-06-27
A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Completed